Aug 10, 2026 06:41AM
Aug 6, 2026 04:01PM
May 7, 2026 04:01PM
Apr 19, 2026 06:00PM
Apr 19, 2026 06:00PM
Apr 19, 2026 06:00PM
Apr 19, 2026 06:00PM Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Mar 9, 2026 09:18AM
Mar 9, 2026 07:00AM
Mar 9, 2026 07:00AM
Dec 19, 2025 09:06AM
Nov 16, 2025 03:00PM
Sep 11, 2025 08:18AM
Jul 29, 2025 06:30AM Compass Pathways adds Justin Gover to board of directors
Jul 29, 2025 06:30AM
Apr 12, 2025 04:00AM
Jan 6, 2025 10:35AM
Dec 21, 2024 10:00AM
May 9, 2024 04:01PM
Feb 29, 2024 04:01PM
May 9, 2023 04:01PM Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Jan 9, 2023 08:13AM
Jan 9, 2023 08:00AM
Jan 9, 2023 08:00AM
Nov 8, 2022 04:01PM
Nov 8, 2022 04:01PM
Nov 3, 2022 08:30AM
Nov 3, 2022 08:30AM Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
Aug 9, 2022 04:01PM
Aug 9, 2022 04:01PM
Jun 21, 2022 07:01AM
Jun 21, 2022 07:00AM
Jun 21, 2022 07:00AM
May 10, 2022 04:01PM
May 10, 2022 04:01PM Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 12, 2022 06:37AM
Mar 1, 2022 04:01PM
Mar 1, 2022 04:01PM
Jan 19, 2022 06:04PM
Jan 12, 2022 08:04AM
Jan 12, 2022 08:01AM
Jan 12, 2022 08:00AM Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
Jan 12, 2022 08:00AM
Jan 10, 2022 08:34AM
Jan 10, 2022 08:30AM
Jan 10, 2022 08:30AM
Dec 3, 2021 07:01AM
Dec 3, 2021 07:00AM
Dec 3, 2021 07:00AM Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
Nov 10, 2021 04:01PM

328,149 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All